Organisation: AstraZeneca

Leveraging injunctive relief in pharmaceutical patent disputes in China

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

Preliminary injunctions play a pivotal role in pharma patent infringement suits, serving as a crucial procedural tool for patentees to protect their IP rights. However, these offer significant advantages, pharma companies must exercise caution due to the risks associated with wrongful preservation.

24 June 2024

Pfizer unit awarded $108 million for AstraZeneca infringement by Delaware jury

But big money pharma patent damages have a habit of being overturned

21 May 2024

FTC opposes 300 more Orange Book patents

The US Federal Trade Commission is ramping up pressure on pharma patentees

02 May 2024

IAM’s Market Makers of 2023

Via Licensing Alliance’s Heath Hoglund takes the top spot in our annual ranking of the patent market’s most innovative and influential deal makers and decision takers

14 March 2024

Specialist Chapter: Trends and Strategies in Global Pharma and Biotech Patent Litigation

Featured in The Patent Litigation Review 2024

International patent protection is now part-and-parcel for any significant drug or therapeutic, and, as a result, disputes over patent ownership and infringement now regularly implicate a myriad of related laws across international venues. In recent years, there has been a trend towards more complex and high-stakes global patent disputes in the pharmaceutical industry, including parallel litigation across multiple jurisdictions.

29 January 2024

Package inserts prove crucial in patent linkage litigation in Taiwan

A deep dive into the relevant case law suggests that courts in Taiwan take the indications listed in package inserts into careful consideration when determining whether a generic drug falls within the disputed patent's scope, so generic drug companies should be cautious when adopting a design-around strategy.

20 December 2023

FTC challenges 100 patent listings, tightening screws on pharma companies

The commission recently vowed to take action on alleged anticompetitive IP tactics

13 November 2023

$227 million Apollo Therapeutics investment is a major boost for innovative tech transfer approach

Pathbreaking joint venture between academia and Big Pharma addresses university IP monetisation challenges

12 September 2023

What AI means for the life sciences space

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

Considered as a significant boost to the life sciences space, AI and machine learning are being increasingly integrated into many scientific fields, helping companies to provide faster, cheaper solutions with a wider public reach, and contributing to IP rights portfolio creation and management.

25 August 2023

Bristol-Myers’ $560 million settlement is yet another success for its patent licensing campaign

AstraZeneca is the third Big Pharma company to pay BMS a nine-figure sum for the use of its immuno-oncology patents

04 August 2023